Personalising radiation therapy in oesophageal cancer
Research type
Research Study
Full title
Personalising radiation therapy in oesophageal cancer: 'a bench to bedside approach'
IRAS ID
185619
Contact name
Simon Lord
Contact email
Sponsor organisation
Research and Development Department, Oxford University Hospitals NHS Trust
ISRCTN Number
47718479
Clinicaltrials.gov Identifier
EUDRACT, 2006-002241-37; ISRCTN, 47718479
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
SCOPE 1 was a UK randomised clinical trial that completed recruitment of 258 patients in February 2012. The aim of the study was to understand whether, for patients with cancer of the oesophagus, the addition of the drug cetuximab to standard chemo-radiotherapy improved patient survival compared to chemo-radiation alone. The study contained a translational element that involved the prospective collection of biopsies via endoscopic ultrasound and blood samples prior to chemo-radiation and also biopsies via endoscopy 12 weeks following chemo-radiotherapy. There was a requirement within the protocol for separate approval for translational projects using these samples. In this study we wish to use these samples to identify potential markers of resistance to cetuximab and chemo-radiotherapy, understand better the DNA damage caused by chemo-radiotherapy, examine for markers of prognosis and better understand the drivers of oesophageal cancer growth and development.
REC name
North of Scotland Research Ethics Committee 1
REC reference
15/NS/0107
Date of REC Opinion
13 Oct 2015
REC opinion
Favourable Opinion